Shanghai-based CataX AI raised CN¥40 million in a Seed round. Qiming Venture Partners incubated the company and was the sole investor. The startup builds AI agents for clinical drug development.
Clinical-of-One model
CataX AI calls its operating model Clinical-of-One. A clinical lead oversees each program with support from specialists and AI agents. Human experts make the key decisions.
What the AI agents do
The AI agents review research, draft documents, and process data. They support the clinical lead across each program. The company aims to reuse what it learns across programs.
Development plans
CataX AI plans to license or co-develop drug candidates at the preclinical or early clinical stage. It will advance those candidates through clinical proof of concept. The company focuses on clinical development rather than drug discovery.
Founder and CEO Wang Zilong has a background in clinical medicine and AI research at Microsoft Research Asia. Co-founder Jiang Zhemin brings more than 15 years of clinical development experience. The two founders combine clinical and AI expertise.